Lupin Sustainability Profile
Lupin Limited, commonly referred to as Lupin, is a prominent global player in the pharmaceutical industry, headquartered in Mumbai, India. Founded in 1968, the company has established a strong presence in key operational regions, including North America, Europe, and Asia. Lupin is renowned for its diverse portfolio, which encompasses generic and branded formulations, biotechnology products, and active pharmaceutical ingredients (APIs). With a commitment to innovation, Lupin has achieved significant milestones, including numerous approvals from regulatory authorities worldwide. The company is particularly noted for its leadership in the anti-TB and cardiovascular segments, offering unique products that cater to unmet medical needs. As a result, Lupin has secured a competitive market position, consistently ranking among the top generic pharmaceutical companies globally.
DitchCarbon Score
How does Lupin's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Lupin's score of 51 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Lupin's reported carbon emissions
In 2024, Lupin's total carbon emissions amounted to approximately 1.23 billion kg CO2e, comprising 61,474,000 kg CO2e from Scope 1, 263,905,000 kg CO2e from Scope 2, and 901,520,000 kg CO2e from Scope 3 emissions. This reflects a commitment to transparency in their environmental impact across all scopes of emissions. Lupin has set an ambitious target to reduce its Scope 1 and Scope 2 greenhouse gas emissions by 15% by 2030, starting from a baseline year of 2021. This commitment aligns with their broader sustainability goals within the pharmaceutical sector, where they aim to enhance their environmental performance. In 2023, the company reported total emissions of approximately 1.27 billion kg CO2e, with Scope 1 emissions at 86,910,000 kg CO2e, Scope 2 at 323,845,000 kg CO2e, and Scope 3 at 854,936,000 kg CO2e. The data indicates a proactive approach to managing and reducing their carbon footprint. Lupin is also a signatory to the Climate Pledge, reinforcing their commitment to sustainability and climate action. The emissions data is not cascaded from any parent organization, ensuring that the figures reflect Lupin's direct operational impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 103,887,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 371,883,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 680,968,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Lupin's Industry?
How Carbon Intensive is Lupin's Location?
Lupin's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Lupin has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Lupin's sustainability data and climate commitments